{'fraction_non_alphanumeric': 0.04641775983854692, 'fraction_numerical': 0.03128153380423814, 'mean_word_length': 5.702702702702703, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Echocardiographic measurements of hemodynamic effects and pharmacokinetics of prenalterol (author's transl)].

The dose-dependent haemodynamic effects and pharmacokinetics and parenteral prenalterol (0.5-10 microgram/kg/min), a new cardioselective beta-1-adrenoceptor agonist, have been studied in 10 healthy volunteers by computed echocardiography. Prenalterol induced a dose-dependent strong and persistent increase in contractility (FV 46%, VCF70 64%, STI 12%), heart index (46%) and heart rate (27%) and a moderate not significant decrease in VED (14%). Afterload and mean arterial blood pressure was nearly unaltered. The hemodynamically effective threshold concentration of prenalterol in plasma was 20-30 nmol/l, the mean value of maximum concentration 493 nmol/l; 1 hour after stopping the infusion prenalterol plasma level was about 90 nmol/l. A strong linear correlation between the haemodynamic alterations and the logarithm of prenalterol plasma concentrations was not apparent.